Pfizer Demerger of Consumer Healthcare JV; Haleon to Be Listed (Pfizer Exits 32% Stake)

Crown Aesthetics (Crown Laboratories) Acquires Select Assets from Healeon LLC (Bimini Health Tech)

July 23, 2024

Medical Devices

Crown Aesthetics, a Crown Laboratories company, has acquired select assets and technology from Healeon LLC, a subsidiary of Bimini Health Tech, to strengthen its ProGen PRP Eclipse platelet-rich plasma (PRP) offering. The asset purchase expands Crown's PRP device portfolio, supports new product development, and aims to extend Crown's geographic and production capabilities in the regenerative and aesthetic medicine markets.

Dr. Reddy's to Acquire Haleon's Nicotinell Global NRT Portfolio (Outside the United States)

June 26, 2024

Healthcare Services

Dr. Reddy’s Laboratories SA has signed a definitive agreement to purchase Haleon’s Haleon group company Northstar Switzerland SARL to acquire Haleon’s global Nicotinell nicotine replacement therapy (NRT) brand portfolio outside the United States. The deal includes Nicotinell plus local leading brand names (Nicabate, Habitrol, Thrive) and applicable pipeline products, with about GBP 217 million revenue reported for the portfolio in CY23.

HUTCHMED Divests 45% Stake in Shanghai Hutchison Pharmaceuticals to GP Health Service Capital and Shanghai Pharmaceuticals Holding

January 3, 2025

Pharmaceuticals

HUTCHMED agreed to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for about US$608 million in cash to GP Health Service Capital Co. and Shanghai Pharmaceuticals Holding. The divestment allows HUTCHMED to reallocate capital to its core oncology and ATTC (antibody-targeted therapy conjugate) pipeline and accelerate its path to profitability.

Merck Acquires Pandion Therapeutics

February 25, 2021

Biotechnology

Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.

Juvisé Pharmaceuticals Acquires Ponvory (ex-US/Canada) from Actelion; Bpifrance and Pemberton Invest in Juvisé

March 26, 2024

Pharmaceuticals

Juvisé Pharmaceuticals has acquired global commercial rights (excluding the United States and Canada) to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd., a Johnson & Johnson company. To fund the transaction, French sovereign fund Bpifrance and private credit manager Pemberton Asset Management took minority stakes in Juvisé; Juvisé will commercialize and assume manufacturing duties for Ponvory in Europe.

PureHealth Acquires 60% Stake in Hellenic Healthcare Group

October 7, 2025

Healthcare Services

PureHealth Holding PJSC agreed to acquire a 60% stake in Hellenic Healthcare Group (HHG), valuing HHG at about USD 2.3 billion. The acquisition integrates HHG’s hospital and diagnostic-centre footprint in Greece and Cyprus into PureHealth’s global healthcare platform.